103628-46-2 (磺马曲坦,Sumatriptan)

磺马曲坦;舒马曲坦;6-氯-2-苯基-4-喹啉甲酰氯;琥珀酸舒马普坦;琥珀酸舒马普坦(注射剂);舒巴曲坦;舒马普坦;舒马曲坦 USP标准品;舒马曲坦-D6;舒马曲坦系统适应性 EP标准品;3-[2-(二甲氨基)乙基]-N-甲基-1H-吲哚-5-甲烷碘酰胺;4-苯肼-N-甲基甲烷磺;舒马曲坦 化学名;舒马曲坦杂质H;3-[2-(二甲胺基)乙基]-N-甲基-1H-吲哚-5-甲基磺酰胺;舒马坦;琥珀酸盐;舒马曲坦碱;舒马坦琥珀酸;

Sumatriptan;3-[2-(Dimethylamino)ethyl]-N-methyl-1H-indole-5-methanesulfonamide;Sumatriptan Impurity H;IMIGRAN;IMITREX;SUMATRIPTAN BASE;1-[3-(2-Dimethylaminoethyl)-1H-indol-5-yl]-N-methyl-methanesulfonamide;gr43175;gr43175x;SuMatriptan Maxalt;Sumatriptan (50 mg);Imigran,Imitrex;SUMATRIPTAN [MART.];3-[2-(dimethylamino)ethyl]-N-methyl-1H-indole -5-methanesulphonamide;Tosymra (nasal spray);SumatriptanSuccinate;SUMATRIPTAN [WHO-DD];3-(2-(Dimethylamino)ethyl)-N-methylindole-5-methanesulfonamide;HMS2231B21;L000584;1-(3-(2-(dimethylamino)ethyl)-1H-indol-5-yl)-N-methylmethanesulfonamide;FT-0631027;1-{3-[2-(dimethylamino)ethyl]-1H-indol-5-yl}-N-methylmethanesulfonamide;MLS001195659;{3-[2-(dimethylamino)ethyl]-1H-indol-5-yl}-N-methylmethanesulfonamide;NCGC00095838-03;FT-0674779;1-[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]-N-methylmethanesulfonamide;MLS001304742;SCHEMBL1482;AVP 825;CS-0009565;BS164424;BIDD:GT0248;BRD-K50938287-001-01-7;BSPBio_002304;GTPL54;NCGC00095838-02;Sumatriptanum [INN-Latin];DTXCID303628;CHEMBL128;SUMATRIPTAN [INN];BDBM50005835;1H-Indole-5-methanesulfonamide, 3-[2-(dimethylamino)ethyl]-N-methyl-;SMR000596517;N02CC01;DTXSID4023628;NCGC00095838-01;(3-[2-(Dimethylamino)ethyl]-1H-indol-5-yl)-N-methylmethanesulfonamide #;AKOS015894924;SUMATRIPTAN [VANDF];SUMATRIPTAN [USP-RS];1H-Indole-5-methanesulfonamide, 3-(2-(dimethylamino)ethyl)-N-methyl-;AMY17769;AVP-825;SUMATRIPTAN [HSDB];AVP825;Sumatriptanum (INN-Latin);Sumatriptan- Bio-X;Tox21_111528;Sumatriptan (JAN/USP/INN);Imitrex (TN);UNII-8R78F6L9VO;SUMATRIPTAN (USP-RS);HSDB 7742;SUMATRIPTAN (MART.);3-[2-(dimethylamino)ethyl]-N-methyl-1H-indole-5-methanesulphonamide;SUMATRIPTAN [ORANGE BOOK];Q416978;NS00009397;AB00698285_15;TOSYMRA;C90357;Imigran (TN);HMS3369A05;BCP02237;3-[2-(Dimethylamino)ethyl]-N-methy-1H-indole-5-methanesulfonamide;(3-[2-(Dimethylamino)ethyl]-1H-indol-5-yl)-N-methylmethanesulfonamide;8R78F6L9VO;Zecuity;AB00698285-13;1-[3-(2-dimethylaminoethyl)-1H-indol-5-yl]-N-methylmethanesulfonamide;SUMATRIPTAN [MI];GR 43175;3-(2-(DIMETHYLAMINO)ETHYL)-N-METHY-1H-INDOLE-5-METHANESULFONAMIDE;3-[2-(Dimethylamino)ethyl]-N-methylindole-5-methanesulfonamide;DB00669;EN300-123008;HY-B0121B;(3-(2-(dimethylamino)ethyl)-1H-indol-5-yl)-N-methylmethanesulfonamide;CAS-103628-46-2;SUMATRIPTAN [JAN];NCGC00095838-04;J-001014;SPECTRUM1505372;Sumatriptan (USP:INN:BAN);CCG-230331;103628-46-2;AB00698285_14;DFN-11;GR 43175X;Sumax;CHEBI:10650;C07319;Sumatriptanum;D00451;Imigran Recovery;3-(2-(Dimethylamino)ethyl)-N-methyl-1H-indole-5-methanesulfonamide;AB00698285-12;GR-43175;Sumatran;BRN 6930870;SUMATRIPTAN (USP MONOGRAPH);Tox21_111528_1;SBI-0206837.P001;1-(3-(2-dimethylaminoethyl)-1H-indol-5-yl)-N-methyl-methanesulfonamide;Sumatriptan [USP:INN:BAN];DFN-11 (SUMATRIPTAN INJECTION);SUMATRIPTAN [USP MONOGRAPH];BRD-K50938287-036-12-0;BRD-K50938287-001-09-0;BRD-K50938287-036-13-8;STL451003;

MFCD00866222

KQKPFRSPSRPDEB-UHFFFAOYSA-N

1S/C14H21N3O2S/c1-15-20(18,19)10-11-4-5-14-13(8-11)12(9-16-14)6-7-17(2)3/h4-5,8-9,15-16H,6-7,10H2,1-3H3

S(CC1C=CC2=C(C=1)C(=CN2)CCN(C)C)(NC)(=O)=O

29280090

为5-羟色胺受体活动药，主要作用方式为选择性地收缩颅侧血管。用于偏头痛。

下列腈化物在二甲胺的甲醇溶液中，10%钯-炭催化下，室温氢化24h，得舒马普坦。